T1	intervention 206 215	denosumab
T2	control 223 243	zoledronic acid (ZA)
T4	eligibility 255 311	patients with advanced breast cancer and bone metastases
T5	total-participants 604 608	2046
T6	outcome 836 849	pain severity
T8	outcome 1268 1303	time to increased pain interference
T9	outcome 1402 1426	time to pain improvement
T10	outcome 1445 1480	time to decreased pain interference
T11	outcome 1576 1589	analgesic use
T12	iv-cont-mean 1024 1034	8.5 months
T13	cv-cont-mean 1040 1050	7.4 months
T14	iv-cont-mean 1209 1219	9.7 months
T15	cv-cont-mean 1223 1233	5.8 months
T16	iv-cont-mean 1358 1369	16.0 months
T17	cv-cont-mean 1375 1386	14.9 months
T18	condition 0 4	Pain
T3	outcome 964 986	time to pain worsening
T7	outcome 1127 1162	progression to moderate/severe pain
